Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

Table 2 WHO treatment outcomes by bedaquiline treatment in MDR-TB patients in South Africa

WHO outcomes, n (%), and 95% CIs^a	Bedaquiline N = 3739^b	No bedaquiline N = 2231^b
Cured	1934 (51.7) 50.1, 53.3	850 (38.1) 36.1, 40.2
Treatment completed	567 (15.2) 14.0, 16.4	252 (11.3) 10.0, 12.7
Died	577 (15.4) 14.3, 16.6	572 (25.6) 23.8, 27.5
Lost to follow-up	553 (14.8) 13.7, 16.0	465 (20.8) 19.2, 22.6
Treatment failed	108 (2.9) 2.4, 3.5	92 (4.1) 3.3, 5.0
Treatment success (cured + treatment completed)	2501 (66.9) 65.4, 68.4	1102 (49.4) 47.5, 51.4

^aThe 95% CI is based on the Clopper-Pearson exact binomial method
^bThe 11 patients excluded from the evaluable population were 4 patients that were still on treatment (all bedaquiline-treated) and 7 patients with missing treatment outcome (4 bedaquiline-treated patients and 3 non-bedaquiline-treated patients)

ISSN: 1471-2334